0001209191-17-008916.txt : 20170208
0001209191-17-008916.hdr.sgml : 20170208
20170208194344
ACCESSION NUMBER: 0001209191-17-008916
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170206
FILED AS OF DATE: 20170208
DATE AS OF CHANGE: 20170208
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bozigian Haig P.
CENTRAL INDEX KEY: 0001423837
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 17584066
MAIL ADDRESS:
STREET 1: 12790 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-02-06
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001423837
Bozigian Haig P.
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Development Officer
Common Stock
2017-02-06
4
S
0
963
43.14
D
117666
D
Stock Option
43.24
2017-02-06
4
A
0
76800
0.00
A
2027-02-06
Common Stock
76800
76800
D
Restricted Stock Option
2017-02-06
4
A
0
10600
0.00
A
Common Stock
10600
10600
D
Sale of 963 shares of common stock issued upon vesting of 2550 restricted stock units to cover withholding taxes with the balance of the shares (1587) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.65 to $43.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2017 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.
Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.
The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021.
/s/ Darin Lippoldt, Attorney-In-Fact
2017-02-08